KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Interest Expenses (2016 - 2025)

Novavax has reported Interest Expenses over the past 16 years, most recently at $5.8 million for Q4 2025.

  • Quarterly results put Interest Expenses at $5.8 million for Q4 2025, down 23.22% from a year ago — trailing twelve months through Dec 2025 was $22.5 million (up 12.31% YoY), and the annual figure for FY2025 was $22.5 million, up 12.31%.
  • Interest Expenses for Q4 2025 was $5.8 million at Novavax, up from $5.5 million in the prior quarter.
  • Over the last five years, Interest Expenses for NVAX hit a ceiling of $7.6 million in Q4 2024 and a floor of $2.9 million in Q3 2023.
  • Median Interest Expenses over the past 5 years was $4.9 million (2021), compared with a mean of $4.9 million.
  • Biggest five-year swings in Interest Expenses: plummeted 49.89% in 2023 and later skyrocketed 84.24% in 2024.
  • Novavax's Interest Expenses stood at $5.1 million in 2021, then decreased by 10.45% to $4.6 million in 2022, then dropped by 10.52% to $4.1 million in 2023, then skyrocketed by 84.24% to $7.6 million in 2024, then decreased by 23.22% to $5.8 million in 2025.
  • The last three reported values for Interest Expenses were $5.8 million (Q4 2025), $5.5 million (Q3 2025), and $5.5 million (Q2 2025) per Business Quant data.